Bolt Biotherapeutics, Inc. (BOLT): Price and Financial Metrics
BOLT Price/Volume Stats
Current price | $1.40 | 52-week high | $2.03 |
Prev. close | $1.22 | 52-week low | $0.84 |
Day low | $1.22 | Volume | 558,200 |
Day high | $1.47 | Avg. volume | 118,152 |
50-day MA | $1.16 | Dividend yield | N/A |
200-day MA | $1.14 | Market Cap | 53.38M |
BOLT Stock Price Chart Interactive Chart >
BOLT POWR Grades
- BOLT scores best on the Sentiment dimension, with a Sentiment rank ahead of 77.22% of US stocks.
- The strongest trend for BOLT is in Growth, which has been heading down over the past 174 days.
- BOLT's current lowest rank is in the Momentum metric (where it is better than 19.59% of US stocks).
BOLT Stock Summary
- BOLT BIOTHERAPEUTICS INC's stock had its IPO on February 5, 2021, making it an older stock than just 9.86% of US equities in our set.
- Of note is the ratio of BOLT BIOTHERAPEUTICS INC's sales and general administrative expense to its total operating expenses; only 11.4% of US stocks have a lower such ratio.
- As for revenue growth, note that BOLT's revenue has grown 49.15% over the past 12 months; that beats the revenue growth of 90.84% of US companies in our set.
- Stocks that are quantitatively similar to BOLT, based on their financial statements, market capitalization, and price volatility, are STRO, CRBU, CUE, MRUS, and RGNX.
- Visit BOLT's SEC page to see the company's official filings. To visit the company's web site, go to www.boltbio.com.
BOLT Valuation Summary
- In comparison to the median Healthcare stock, BOLT's price/earnings ratio is 102.06% lower, now standing at -0.6.
- Over the past 35 months, BOLT's EV/EBIT ratio has gone up 16.9.
Below are key valuation metrics over time for BOLT.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
BOLT | 2023-12-29 | 5.9 | 0.3 | -0.6 | -0.7 |
BOLT | 2023-12-28 | 5.6 | 0.3 | -0.6 | -0.7 |
BOLT | 2023-12-27 | 5.5 | 0.3 | -0.6 | -0.7 |
BOLT | 2023-12-26 | 5.2 | 0.3 | -0.5 | -0.7 |
BOLT | 2023-12-22 | 5.3 | 0.3 | -0.5 | -0.7 |
BOLT | 2023-12-21 | 5.3 | 0.3 | -0.5 | -0.7 |
BOLT Price Target
For more insight on analysts targets of BOLT, see our BOLT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $39.75 | Average Broker Recommendation | 1.2 (Strong Buy) |
Bolt Biotherapeutics, Inc. (BOLT) Company Bio
Bolt Biotherapeutics, Inc. operates as a biotechnology company. The Company develops immune-stimulating antibody conjugates, a new class of cancer therapeutics, which systemically-administered and uncover the immune system to induce anti-tumor immunity. Bolt Biotherapeutics serves healthcare industry in the United States.
Latest BOLT News From Around the Web
Below are the latest news stories about BOLT BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate BOLT as an investment opportunity.
Pacira Appoints Frank D. Lee as Chief Executive Officer-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (th |
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersPoster detailing trial design and rationale to be presented at the 2023 San Antonio Breast Cancer Symposium on Wednesday, December 6 REDWOOD CITY, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of |
Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateBDC-1001 program advances in multiple Phase 2 clinical studies in patients with HER2-positive colorectal, gastric, endometrial, and metastatic breast cancer, with recent updated data at ESMO showing improved clinical efficacy and longer durability; FDA Orphan Drug Designation granted for the BDC-1001 in gastric cancersFirst patient administered BDC-3042 in a Phase 1/2 dose-escalation and expansion clinical studyCash balance of $141.4 million as of September 30, 2023 anticipated to fund key miles |
Bolt Biotherapeutics to Present at Stifel 2023 Healthcare ConferenceREDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, Nov. 14, 2023, at 8:35 a.m. EDT (5:35 a.m. PDT) in New York, New York. A live webcast of the presentation will be available on the Events and Presentations page of Bolt’s website at |
BOLT Price Returns
1-mo | 16.67% |
3-mo | 25.00% |
6-mo | 34.62% |
1-year | 8.53% |
3-year | -94.59% |
5-year | N/A |
YTD | 25.00% |
2023 | -13.85% |
2022 | -73.47% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...